Advanced search
Publication Cover
Experimental Lung Research Volume 28, 2002 - Issue 7
Submit an article Journal homepage
82
Views
49
CrossRef citations to date
0
Altmetric
Research Article

ASSESSMENT OF THE PROTECTIVE EFFECT OF AMIFOSTINE ON RADIATION-INDUCED PULMONARY TOXICITY

Zeljko Vujaskovic Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina
,
Qin Fu Feng Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina
,
Zahid N. Rabbani Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina
,
Thaddeus V. Samulski Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina
,
Mitchell S. Anscher Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina
&
David M. Brizel Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina
Pages 577-590 | Published online: 02 Jul 2009

  • Carmel RJ, Kaplan HS: Mande irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications. Cancer. 1976;37:2813-2825.
  • Lingos TI, Recht A, Vicini F, Abner A, Silver B, Harris JR: Radiation pneumonias in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1991;21:355-360.
  • Martel MK, Ten Haken RK, Hazuka MB, Turrisi AT, Fraass BA, Lichter AS: Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonias. Int J Radiat Oncol Biol Phys. 1994:28:575-581.
  • Morgan GW, Freeman AP, McLean RG, Jarvie BH, Giles RW: Late cardiac, thyroid, and pulmonary sequelae of mande radiotherapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1985;11: 1925-1931.
  • Penn CR, Hope-Stone HF: The role of radiotherapy in the management of malignant thymoma. Br J Surg. 1972:59:533-539.
  • Roach M 3rd, Gandara Dr, You HS, Swift PS, Kroll S, Shrieve DC., Wara WM, Margolis L, Phillips TL: Radiation pneumonias following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin OncoL 1995; 13:2606-2612.
  • Rothwell RI, Kelly SA, Joslin CA: Radiation pneumonias in patients treated for breast cancer. Radiother Oncol 1985;4:9-14.
  • Curran WJJr., Moldofsky PJ, Solin, LJ: Observations on die predictive value of perfusion lung scans on post-irradiation pulmonary function among 210 patients with bronchogenic carcinoma. Int J Radiat Oncol Biol Phys. 1992:24:31-36.
  • Kimsey FC, Mendenhall NP, Ewald LM, Coons TS and Layon AJ: Is radiation treatment volume a predictor for acute or late effect on pulmonary function? A prospective study of patients treated with breast-conserving surgery and postoperative irradiation. Cancer. 1994;73:2549-2555.
  • Rubenstein JH, Richter MP, Moldofsky PJ, Solin LJ: Prospective prediction of post-radiation therapy lung function using quantitative lung scans and pulmonary function testing. IntJ Radiat Oncol Biol Phys. 1988;15:83-87.
  • Shapiro SJ, Shapiro SD, Mill WB, Campbell EJ: Prospective study of long-term pulmonary manifestations of mantle irradiation. IntJ Radiat Oncol Biol Phys. 1990; 19:707-714.
  • Smith LM, Mendenhall NP, Cicale MJ, Block ER, Carter RI, Million RR: Results of a prospective study evaluating the effects of mantle irradiation on pulmonary function. Int J Radiat Oncol Biol Phys. 1989;16:79-84.
  • Watchie J, Coleman CN, Raffin TA, Cox RS, Raubitschek AA, Fahey T, Hoppe RT, Van Kessel A: Minimal long-term cardiopulmonary dysfunction following treatment for Hodgkin's disease. IntJ Radiat Oncol Biol Phys. 1987;13:517-524.
  • Yuhas JM: Radioprotective and toxic effects of WR2721 on the development of immunocompetent cells. Cell Immunol 1972;4:256-263.
  • YuhasJM: Radiotherapy of experimental lung tumor in the presence and absence of radioprotective drug S-2(3-aminopropylamino)-ethyphosphorothioic acid (WR 2721). J Natl Cancer Inst. 1973;50: 69-78.
  • Travis EL, Parkins CS, Holmes SJ, Down JD, Fowler JF: WR-2721 protection of pneumonias and fibrosis in mouse lung after single doses of radiation. IntJ Radiat Oncol Biol Phys. 1984; 0:243-261.
  • Travis EL, Meistrich ML, Finch Neimeyer MV, Watkins TL, Kiss I: Late functional and biochemical changes in mouse lung after irradiation: differential effects of WR-2721. Radiat Res. 1985;! 03: 219-231.
  • Travis EL, Newman RA, Helbing SJ: WR 2721 modification of type II cell and endothelial cell functing in mouse lung after single doses of radiation. IntJ Radiat Oncol Biol Phys. 1987;13:13551359.
  • Muas L, Hunter N, Reid BO, Thames HD Jr: Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissue in a fibrosarcoma in mice. Cancer Res. 1982;42:1888-1897.
  • Parkins C, Fowler JF, Denekamp J: Low radioprotection by thiol in lung: the role of local tissue oxygenation. EUT J Cancer Clin Oncol 1983;8:1169-1172.
  • Yuhas JM, Spellman JM, CuIo F: The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials. 1980;3:211-216.
  • Rasey JS, Grunbaum Z, Krohn KA: Biodistribution of the radioprotective drug S-labeled 3-amino-2hydroxy-propyl phosphorothioate (WR77913). Radiat Res. 1985;102:130-137.
  • Barcellos-Hoff MH, Dix TA: Redox-mediated activation of latent transforming growth factor-ß1. MoI Endocrinol 1996;9:1077-1083.
  • Law MP, Hornsey S, Field SB: Collagen content of lungs of mice after x-ray irradiation. Radiat Res. 1976;65:60-70.
  • Phillips TL, Kane L, Utley J: Radioprotection of tumor and normal tissue by thiophosphate compounds. Cancer. 1972;32:528-535.
  • Down JD, Laurent GJ, McAnulty RJ, Steel GG: Oxygen-dependent protection of radiation lung damage in mice by WR 2721. IntJ Radiat BioL 1984;5:597-607.
  • Vujaskovic Z, Down JD, van t' Veld AA, Mooyaart EL, Meertens H, Piers DA, Szabo BG, Konings AW: Radiological and functional assessment of radiation-induced lung injury in the rat Exp Lung Res. 1998:24:137-148.
  • Franko AJ, Sharplin J: Development of fibrosis after lung irradiation in relation to inflammation and lung function in a mouse strain prone to fibrosis, Radiat Res. 1994;140:347-355.
  • Pickrell JA, Diel JH, Slauson DO, Halliwell WH, MauderlyJL: Radiation-induced pulmonary fibrosis resolves spontaneously if dense scars are not formed. Exp MoI Pathol. 1983;38:22-32.
  • Ward WF, Sharplin J, Franko AJ, Hinz JM: Radiation-induced pulmonary endothelial dysfunction and hydroxyproline accumulation in four strains of mice. Radiat Res. 1989;120:113-120.
  • van Rongen E, Madhuizen HT, Tan CH, Durham SK, Gijbels MJ: Early and late effects of fractionated irradiation and the kinetics of repair in rat lung. Radiother OncoL 1990;! 7:323-337.
  • Karvonen RL, Fernandez MF, Maughan RL, Palmer KC, Fernandez-Madrid I: An animal model of pulmonary radiation fibrosis with biochemical, physiologie, immunologie, and morphologie observations. Radiat Res. 1987;111:68-80.
  • Nici L, Santos-Moore A, Kuhn C, Calabresi P: Modulation of bleomycin-induced pulmonary toxicity in me hamster by the antioxidant amifostine. Cancer. 1998;83:2008-2014.
  • Miller GG, Kenning JM, Dawson DT: Radiation-induced changes in collagen isotypes I, and IV in the lung of LAFl mouse: effects of time, dose and WR-2721. Radiat Res. 1988;! 15515-532.
  • Ortiz LA, Lasky JA, Safah H, Reyes, M, Miller A, Lungarella G, Friedman M: Exacerbation of bleomycin-induced lung injury in mice by amifostine. Am J Physiol. 1999;277:L1239-L1244.
  • Border WA, Ruoslahti E: Transforming growth factor-ß in disease: the dark side of tissue repair. J Clin Invest 1992;90:1-7.
  • Finkelstein J, Johnston C, Baggs R, Rubin P: Early alteration in extracellular matrix and transforming growth factor p gene expression in mouse lung indicative of late radiation fibrosis. IntJ Radit Oncol Biol Phys. 1994;28:621-631.
  • Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN: A perpetual cascade of cytokines post irradiation leads to pulmonary fibrosis. IntJ Radit Oncol Biol Phys. 1995;33:99-109.
  • Hoyt B, Lazo J: Alterations in pulmonary mRNA encoding pro-collagens, fibronectin, and transforming growth factor beta precede bleomycin-induced pulmonary fibrosis. J Pharmacol Exp Ther. 1988;24:765-771.
  • Hoyt B, Laso J: Early increases in pulmonary mRNA encoding procoUagens and transforming growth factor beta in mice sensitive to cyclophosphamide-induced pulmonary fibrosis. J Pharmacol Exp Ther. 1989;249:38-43.
  • Franko AJ, Sharplin J, Ghahary A, Barcellos-Hoff MH: Immunohistochemical localization of transforming growth factor beta and tumor necrosis factor alpha in the lungs of fibrosis-prone and "non-fibrosing" mice during the latent period and early phase after irradiation. Radit Res. 1997;147:245-256.
  • Burger A, Loftier H, Bamberg M, Rodemann HP: Molecular and cellular basic of radiation fibrosis. IntJ Radiat BioL 1998;73:401-408.
  • Anscher MS, Kong FM, Marks LB, Bentel GC, Jirtle RL Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induce pneumonias. Int J Radiat Oncol Biol Phys. 1997;37:253-258.
  • Anscher MS, Kong FM, Jirtle RL The relevance of transforming growth factor betal in pulmonary injury after radiation therapy. Lung Cancer. 1998;19:109-120.
  • Vujaskovic Z, Down JD, van Waarde MA, van Assen AJ, Szabo BG, Konings AW: Plasma TGF- level in rats after hemithoracic irradiation. Radiother Oncol 1997;44:41-43.
  • Lyons RM, Gentry LE, Purchio AF, Moses HL Mechanism of activation of latent recombinant transforming growth factor pi by plasmin. J Cell Biol 1990;110:1361-1367.
  • Capizzi RL, Aster W: Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experience. EurJ Cancer. 1995;31A(Suppl 1):S8-S13.
  • Liu T, Liu Y, He S, Zhang Z, Klingerman MM: The use of radiation with or without amifostine in advanced rectal cancer. Cancer. 1992;69:2820-2825.
  • Tannehill SP, Mehta MP, Larson M: Phase II clinical trial of amifostine (WR-2721), cisplatin, vinblastine and thoracic radiation therapy for unresectable stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1995;32(Suppl):196.
  • Tannehill SP, Mehta MP: Amifostine and radiation therapy: past, present, and future. Sem OncoL 1996;23(Suppl 8):69-77.
  • Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, ZhangJ, Russell L, Oster W, Sauer R: Phase II Randomized Trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;19:3339-3345.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.